MAP referenced at APPG for Life Sciences

MAP BioPharma’s report Access to Orphan Medicines: A Case for Change was reference at last week’s APPG for Life Sciences meeting.

The All-Party Parliamentary Group (APPG) for Life Sciences meeting, titled ‘Understanding the value of new medicines and diagnostics in the NHS’, included contributions on:

  • the Voluntary Pricing and Access Scheme (VPAS) – Paul Catchpole, ABPI
  • NICE perspectives on VPAS and access to medicines – Sarah Byron, NICE
  • diagnostics and uptake – Darren Stenlake, BIVDA
  • rare diseases and access to medicines – Charlotte Galvin, Amicus Therapeutics

MAP’s report was referenced in suggesting that the uptake of rare medicines is inefficient.

Find out more from Access to Orphan Medicines: A Case for Change here.

Tagged with

Published 22. May 2019 in News, News UK